NYSE - Delayed Quote • USD
Bristol-Myers Squibb Company (BMY)
At close: April 18 at 4:00 PM EDT
Pre-Market: 5:58 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 12 | 17 | 15 | 23 |
| Avg. Estimate | -4.19 | 1.67 | 0.61 | 6.66 |
| Low Estimate | -4.5 | 1.57 | 0.07 | 6.19 |
| High Estimate | -3.08 | 1.83 | 2.1 | 7.38 |
| Year Ago EPS | 2.05 | 1.75 | 7.07 | 0.61 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 16 | 15 | 24 | 23 |
| Avg. Estimate | 10.79B | 10.87B | 43.27B | 43.72B |
| Low Estimate | 10.52B | 10.64B | 42.67B | 42.52B |
| High Estimate | 11.04B | 11.13B | 44.15B | 45.18B |
| Year Ago Sales | 11.34B | -- | 42.37B | 43.27B |
| Sales Growth (year/est) | -4.80% | -- | 2.10% | 1.00% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.97 | 1.98 | 1.61 | 1.44 |
| EPS Actual | 2.05 | 1.75 | 1.82 | 1.6 |
| Difference | 0.08 | -0.23 | 0.21 | 0.16 |
| Surprise % | 4.10% | -11.60% | 13.00% | 11.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -4.19 | 1.67 | 0.61 | 6.66 |
| 7 Days Ago | 1.49 | 1.63 | 6.33 | 6.53 |
| 30 Days Ago | 1.58 | 1.77 | 6.83 | 7.11 |
| 60 Days Ago | 1.47 | 1.66 | 6.38 | 6.66 |
| 90 Days Ago | 1.89 | 1.88 | 7.16 | 7.43 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | 3 |
| Up Last 30 Days | -- | 4 | -- | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 1 | 7 | 5 |
Growth Estimates
| CURRENCY IN USD | BMY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -304.40% | -- | -- | 0.80% |
| Next Qtr. | -4.60% | -- | -- | 9.60% |
| Current Year | -91.40% | -- | -- | 4.50% |
| Next Year | 991.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -3.93% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 13.30% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 4/18/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 2/6/2024 |
| Downgrade | Redburn Atlantic: Buy to Neutral | 2/6/2024 |
| Downgrade | B of A Securities: Buy to Neutral | 1/3/2024 |
| Maintains | B of A Securities: Buy to Buy | 12/27/2023 |
| Downgrade | Cantor Fitzgerald: Overweight to Neutral | 11/15/2023 |
Related Tickers
PFE Pfizer Inc.
25.39
-0.12%
GILD Gilead Sciences, Inc.
66.16
-1.15%
ABBV AbbVie Inc.
164.66
+0.25%
MRK Merck & Co., Inc.
125.23
-0.11%
JNJ Johnson & Johnson
145.74
+0.67%
AMGN Amgen Inc.
262.75
-0.50%
GSK GSK plc
39.27
-0.83%
LLY Eli Lilly and Company
745.95
-0.64%
BIIB Biogen Inc.
190.52
-0.85%
AZN AstraZeneca PLC
68.36
-0.25%